Browse by Author

Browse by Year

Browsing publications by Dr Yvette Drew

Newcastle AuthorsTitleYearFull text
Dr Stuart Rundle
Alice Bradbury
Dr Yvette Drew
Professor Nicola Curtin
Targeting the ATR-CHK1 Axis in Cancer Therapy2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr Yvette Drew
Homologous recombination deficiency and ovarian cancer2016
Dr Ganiy Abdulrahman
Elizabeth Matheson
Dr Yvette Drew
Professor Nicola Curtin
Dr Asima Mukhopadhyay
et al.
Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Elizabeth Matheson
Dr Mo Salehan
Dr Asima Mukhopadhyay
Professor Nicola Curtin
Dr Yvette Drew
et al.
Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer2016
Dr Yvette Drew
Dr Alastair Greystoke
Professor Ruth Plummer
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).2015
Dr Yvette Drew
A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation2015
Dr Yvette Drew
A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation2015
Dr Yvette Drew
The development of PARP inhibitors in ovarian cancer: from bench to bedside2015
123